Tag Archives: NASH

Ultrasound-based Elastography for Non-Invasive Monitoring in Chronic Liver Diseases

Non-invasive, ultrasound-based elastography devices are changing and simplifying regular monitoring for scarring and fibrosis in patients with certain chronic liver diseases, in many cases replacing the need for biopsy.1 Karen L. Krok, M.D., Penn State Hershey Gastroenterology and Hepatology, says, “In patients with an established diagnosis of chronic liver disease, such as hepatitis C or B or nonalcoholic steatohepatitis (NASH), elastography can be used to monitor fibrosis and scarring, with a level of accuracy comparable to biopsy. The procedure is quick, painless and less expensive.”

Ultrasound-based methods of elastography use a vibrating device attached to an ultrasound transducer, which is placed in an intercostal position with the patient lying supine. The velocity of vibration waves (also called shear wave velocity), expressed in kilopascals (kPa), is determined by measuring the time the vibration wave takes to travel to and bounce back from the liver. Shear wave velocity is directly related to tissue stiffness, an indicator of hepatic fibrosis (Figure). Ten successful measurements are required for the test to be reliably interpreted; a median value is generated to indicate the degree of liver fibrosis. Krok says, “It’s like bouncing a tennis ball against a soft versus hard surface. The ball will bounce back more quickly from a firm surface like pavement than it would if it were bounced against something soft, like a pillow.” Continue reading

Comments Off on Ultrasound-based Elastography for Non-Invasive Monitoring in Chronic Liver Diseases

Filed under Patient Care

Lysosomal Acid Lipase Dificiency (LAL-D) in adults: Epidemiologic Multi-Center Study Underway

A multi-center, investigator-initiated epidemiologic study is underway [clinical trial: NCT01633489] aiming to determine the proportion of adults affected by late-onset lysosomal acid lipase deficiency (LAL-D) using definitive genetic testing.

LAL-D is an autosomal recessive disease caused by mutations in the Iipase gene that lead to decreased or absent enzyme activity. Lack of such activity causes lysosomal accumulation of cholesteryl ester in various organs, including the liver, spleen and adrenals, which leads to morbidity and mortality.1 Transplant hepatologist Karen L. Krok, M.D., Penn State Hershey Gastroenterology and Hepatology, explains, “At Penn State Hershey and other study centers in Pennsylvania, adults with cryptogenic cirrhosis or nonalcoholic steatohepatitis [NASH] who are awaiting liver transplant will have the opportunity to be tested for LAL-D. The signs and symptoms of LAL-D are similar to other common conditions; however, 10 to 15 percent of patients have no comorbid condition like hepatitis, obesity, diabetes or alcohol use to explain the disease. (Learn more about clinical features of LAL-D in adults.) Continue reading

Leave a comment

Filed under Research, Treatments